Joint Formulary & PAD

Donepezil hydrochloride - Alzheimers disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral solution
  • Oro-dispersible tablets
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important
Preferred

Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.

Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Donepezil hydrochloride
Indication :
Alzheimers disease
Group Name :
Keywords :
AChE Inhibitors, acetylcholinesterase inhibitors, dementia, alzheimers dementia, Alzheimer's disease
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

As part of the Surrey Heartlands Joint Formulary review, the Surrey Heartlands APC approved a change in traffic light status for patients requiring treatment with donepezil:

  • Blue - on specialist recommendation (previously Amber with shared care for patients who were not suitable for discharge and who required ongoing follow-up with the specialist mental health team)

The prescribing of donepezil for patients who are not suitable for discharge can be carried out by Primary Care but, the specialist mental health team will retain responsibility for the review and follow-up of patients that continue to require specialist input.

Other Indications

Below are listed other indications that Donepezil hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Alzheimers disease.